Key Points
RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter.
The quarter-end value of the Apellis stake was $192.59 million, reflecting the new position added by RTW Investments, LP.
Apellis now represents 1.93% of portfolio AUM, which places it outside the fund’s top five holdings.
- 10 stocks we like better than Apellis Pharmaceuticals ›
RTW Investments initiated a new stake in Apellis Pharmaceuticals (NASDAQ:APLS), acquiring 7,666,764 shares in the fourth quarter, according to a February 17, 2026, SEC filing.
What happened
An SEC filing dated February 17, 2026, shows RTW Investments opened a new position in Apellis Pharmaceuticals during the fourth quarter, buying 7,666,764 shares. The quarter-end value of the stake stood at $192.59 million, reflecting both the share addition and stock price factors.
What else to know
- This was a new position for RTW Investments, LP, with Apellis accounting for 1.93% of 13F reportable AUM as of December 31, 2025.
- Top holdings after the filing:
- NASDAQ:MDGL: $1.16 billion (11.6% of AUM)
- NASDAQ:INSM: $842.85 million (8.4% of AUM)
- NASDAQ:PTCT: $588.42 million (5.9% of AUM)
- NASDAQ:ARGX: $566.38 million (5.7% of AUM)
- NASDAQ:PTGX: $441.86 million (4.4% of AUM)
- As of Friday, Apellis shares were priced at $17.21, down 29% over the past year and well underperforming the S&P 500, which is instead up about 15% in the same period.
Company overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $1 billion |
| Net Income (TTM) | $22.4 million |
| Market Capitalization | $2.2 billion |
| Price (as of Friday) | $17.21 |
Company snapshot
- Apellis Pharmaceuticals develops and commercializes therapeutic compounds targeting the complement system, with key products including pegcetacoplan and EMPAVELI for autoimmune and inflammatory diseases.
- The firm generates revenue primarily through sales of proprietary biopharmaceutical products and collaborative licensing agreements.
- It serves healthcare providers and patients in markets addressing rare diseases such as geographic atrophy, paroxysmal nocturnal hemoglobinuria, and cold agglutinin disease.
Apellis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on innovative therapies for complement-driven diseases. With a robust pipeline and a growing commercial portfolio, the company leverages its expertise in complement inhibition to address significant unmet medical needs. Apellis’s strategic collaborations and targeted approach provide a competitive advantage in the rare disease and specialty therapeutics market.
What this transaction means for investors
This is the kind of setup that tends to separate disciplined biotech investors from momentum chasers. Apellis stock performance has left much to be desired over the past year, but under the hood, there are signals that a disciplined investor might be willing to bet on.
Apellis generated roughly $689 million in product revenue last year, driven largely by its flagship therapy, which alone brought in about $587 million, alongside another $102 million from its second product. That is not early-stage speculation anymore. It is a company with real demand, expanding market share, and growing penetration in rare disease markets.
What makes this move more interesting is where it sits in the broader portfolio. This fund’s top positions lean heavily into high-growth biotech names like Madrigal and Insmed, where clinical upside drives returns. Against that backdrop, a sub 2% position in a commercial-stage name looks like a calculated pivot toward more durable revenue streams without abandoning upside.
Should you buy stock in Apellis Pharmaceuticals right now?
Before you buy stock in Apellis Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apellis Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 21, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Argenx Se. The Motley Fool recommends Protagonist Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
